Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Tissue Engineering _ Stem Cells
Pluri Inc. (NASDAQ: PLUR)*, fomerly, Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Organization & Developments: Pluristem

Parents

2017: FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell_pluristem
2019: Pluristem’s cell therapies head for orbit with NASA deal
2020: 5 Stem Cell Companies Racing Towards COVID-19 ARDS Therapy
Development-stage bio-therapeutics company
Pluristem is developing a pipeline of ready-to-use stem cells derived from discarded human placenta
Takes the controversial aspect out of the equation that embryonic stem cells carry.
The cells, which are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that require no tissue matching prior to administration, are known as PLacental eXpanded (PLX) cells, and are derived using PSTI